136 related articles for article (PubMed ID: 33289381)
1. Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel.
Jones AL; Dhanapala L; Baldo TA; Sharafeldin M; Krause CE; Shen M; Moghaddam S; Faria RC; Dey DK; Watson RW; Andrawis R; Lee NH; Rusling JF
Anal Chem; 2021 Jan; 93(2):1059-1067. PubMed ID: 33289381
[TBL] [Abstract][Full Text] [Related]
2. Immunoarray Measurements of Parathyroid Hormone-Related Peptides Combined with Other Biomarkers to Diagnose Aggressive Prostate Cancer.
Dhanapala L; Joseph S; Jones AL; Moghaddam S; Lee N; Kremer RB; Rusling JF
Anal Chem; 2022 Sep; 94(37):12788-12797. PubMed ID: 36074029
[TBL] [Abstract][Full Text] [Related]
3. Sub-zeptomole Detection of Biomarker Proteins Using a Microfluidic Immunoarray with Nanostructured Sensors.
Dhanapala L; Jones AL; Czarnecki P; Rusling JF
Anal Chem; 2020 Jun; 92(12):8021-8025. PubMed ID: 32433882
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.
Chikkaveeraiah BV; Mani V; Patel V; Gutkind JS; Rusling JF
Biosens Bioelectron; 2011 Jul; 26(11):4477-83. PubMed ID: 21632234
[TBL] [Abstract][Full Text] [Related]
5. Blood-based biomarkers of aggressive prostate cancer.
Liong ML; Lim CR; Yang H; Chao S; Bong CW; Leong WS; Das PK; Loh CS; Lau BE; Yu CG; Ooi EJ; Nam RK; Allen PD; Steele GS; Wassmann K; Richie JP; Liew CC
PLoS One; 2012; 7(9):e45802. PubMed ID: 23071848
[TBL] [Abstract][Full Text] [Related]
6. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
[TBL] [Abstract][Full Text] [Related]
9. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
Ismail HA; Pollak M; Behlouli H; Tanguay S; Bégin LR; Aprikian AG
BJU Int; 2003 Nov; 92(7):699-702. PubMed ID: 14616449
[TBL] [Abstract][Full Text] [Related]
10. Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array.
Malhotra R; Patel V; Chikkaveeraiah BV; Munge BS; Cheong SC; Zain RB; Abraham MT; Dey DK; Gutkind JS; Rusling JF
Anal Chem; 2012 Jul; 84(14):6249-55. PubMed ID: 22697359
[TBL] [Abstract][Full Text] [Related]
11. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
12. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
13. Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins.
Tang CK; Vaze A; Rusling JF
Lab Chip; 2017 Jan; 17(3):484-489. PubMed ID: 28067370
[TBL] [Abstract][Full Text] [Related]
14. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
15. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
Lucarelli G; Rutigliano M; Bettocchi C; Palazzo S; Vavallo A; Galleggiante V; Trabucco S; Di Clemente D; Selvaggi FP; Battaglia M; Ditonno P
J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
[TBL] [Abstract][Full Text] [Related]
16. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
17. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
Xu L; Mao X; Grey A; Scandura G; Guo T; Burke E; Marzec J; Abdu S; Stankiewicz E; Davies CR; Rajan P; Tipples K; Hines J; Chan PY; Campbell D; Wilkinson K; Kudahetti S; Shamash J; Oliver T; Berney D; Shaw G; Lu YJ
J Urol; 2020 Jan; 203(1):73-82. PubMed ID: 31389764
[TBL] [Abstract][Full Text] [Related]
19. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
20. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Horninger W; Klocker H; Mikolajczyk SD
J Urol; 2004 Jun; 171(6 Pt 1):2239-44. PubMed ID: 15126794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
